The Additive Effect of Topical Ciprofloxacin 2% on Intralesional Glucantime Injection in Treatment of Cutaneous Leishmaniasis

Document Type : Original Article (s)

Authors

1 Professor, Department of Dermatology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

2 Assistant Professor, Department of Dermatology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

3 Resident, Department of Dermatology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

4 Associate Professor, Department of Dermatology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

5 Associate Professor, Department of Pharmaceutical Chemistry, School of Pharmacology, Mashhad University of Medical Sciences, Mashhad, Iran

Abstract

Background: Leishmaniasis is endemic in Iran, and Mashhad is one of the most involved cities. Glucantime, prescribed as intralesional or systemic injection, is the most common treatment for cutaneous leishmaniasis. We investigated the additive effect of topical ciprofloxacin on the intralesional injection of glucantime in treatment of cutaneous leishmaniasis.Methods: This randomized clinical trial study was performed on patients with cutaneous leishmaniasis diagnosed by direct smear or biopsy, who referred to Imam Reza and Ghaem teaching hospitals of Mashhad University of Medical Sciences. Patients were randomly allocated into two groups to receive either topical liposomal ciprofloxacin 2% twice daily plus weekly intralesional glucantime or intralesional glucantime alone, for eight weeks. The size of induration and the rate of healing was assessed every week.Findings: There were no significant differences between the groups in cure rate (decrease in induration size equal or more than 75%) (P = 0.410) and the time of healing (P = 0.050) 45 days after the end of treatment.Conclusion: Using topical ciprofloxacin does not have any additive effect on the conventional treatment of cutaneous leishmaniasis.

Keywords

References

  1. Kadir MA, Aswad HS, Al-Samarai AM, Al-Mula GA. Comparison between the efficacy of ivermectin and other drugs in treatment of cutaneous leishmaniasis. Iraqi J Vet Sci 2009; 23(Suppl.2): 175-180.
  2. Asilian A, Sadeghinia A, Faghihi G, Momeni A. Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (Glucantime) vs. cryotherapy and intralesional meglumine antimoniate (Glucantime) alone for the treatment of cutaneous leishmaniasis. Int J Dermatol 2004; 43(4): 281-3.
  3. Wrone DA. Clinical dermatology: A color guide to diagnosis and therapy. JAMA 2012; 307(14): 1534.
  4. Zijlstra EE, el-Hassan AM. Leishmaniasis in Sudan. Post kala-azar dermal leishmaniasis. Trans R Soc Trop Med Hyg 2001; 95(Suppl 1): S59-S76.
  5. Al Hamdi K, Awad AH, Moker HM. Evaluation of intralesional 0.2% ciprofloxacin as a treatment for cutaneous leishmaniasis. East Mediterr Health J 2010; 16(1): 89-93.
  6. Inceboz T, Inceboz U, Ozturk S. Comparative in vitro cytotoxic effects of ornidazole, metronidazole and ciprofloxacin against Trichomonas vaginalis trophozoites. J Chemother 2004; 16(5): 459-62.
  7. Arshad AR, Arshad A. Intralesional ciprofloxacin for cutaneous leishmaniasis: Comparison with meglumine antimoniate. Pak J Med Sci 2011; 27: 566-8.
  8. Romero IC, Saravia NG, Walker J. Selective action of fluoroquinolones against intracellular amastigotes of Leishmania (Viannia) panamensis in vitro. J Parasitol 2005; 91(6): 1474-9.
  9. Slappendel RJ, Teske E. The effect of intravenous or subcutaneous administration of meglumine antimonate (Glucantime) in dogs with leishmaniasis. A randomized clinical trial. Vet Q 1997; 19(1): 10-3.
  10. Slappendel RJ. Prizewinning paper Jubilee Competition: Canine leishmaniasis. Vet Q 1988; 10(1): 1-16.
  11. Longstaffe JA, Guy MW. Canine leishmaniasisUnited Kingdom update. J Small Anim Pract 1986; 27(10): 663-71.
Journal of Isfahan Medical School
Volume 38, Issue 571 - Serial Number 571
March and April 2020
Pages 245-251

Files

History

  • Receive Date: 26 February 2020
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics